Medytox Solutions (MMMS) 10-Q 15 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	11-May-15
Document And Entity Information
Entity Registrant Name	Medytox Solutions, Inc.
Entity Central Index Key	1374536
Document Type	10-Q
Document Period End Date	31-Mar-15
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		29,306,026
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2015

Condensed_Balance_Sheets

Condensed Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current assets:
Cash	$650,505	$2,406,246
Accounts receivable, net	23,833,608	17,463,947
Prepaid expenses and other current assets	187,288	170,353
Deferred tax assets	28,300	28,300
Deposits on acquisitions	0	259,875
Total current assets	24,699,701	20,328,721
Property and equipment, net	7,318,521	7,678,123
Other assets:
Intangible assets	4,428,424	4,436,473
Goodwill	3,278,813	3,139,942
Deposits	216,717	177,495
Total assets	39,942,176	35,760,754
Current liabilities:
Accounts payable	3,057,100	3,356,797
Accrued expenses	2,689,490	2,297,416
Income tax liabilities	8,545,715	8,087,946
Current portion of notes payable	226,684	443,292
Current portion of notes payable, related party	5,990,274	2,620,000
Current portion of capital lease obligation	727,307	962,562
Derivative liability	380,000	380,000
Total current liabilities	21,616,570	18,148,013
Other liabilities:
Notes payable, net of current portion	0	93,392
Capital lease obligations, net of current portion	2,260,564	2,222,625
Deferred tax liabilities	301,800	252,900
Total liabilities	24,178,934	20,716,930
Commitments and contingencies
Stockholders' equity:
Common stock	2,931	2,905
Additional paid-in-capital	5,713,824	5,357,367
Retained earnings	10,046,476	9,562,517
Total Medytox Solutions stockholders' equity	15,763,242	14,922,820
Noncontrolling interest	0	121,004
Total stockholders' equity	15,763,242	15,043,824
Total liabilities and stockholders' equity	39,942,176	35,760,754
Series B Preferred Stock
Stockholders' equity:
Preferred stock, 100,000,000 shares authorized:	1	1
Series D preferred stock
Stockholders' equity:
Preferred stock, 100,000,000 shares authorized:	5	20
Series E preferred stock
Stockholders' equity:
Preferred stock, 100,000,000 shares authorized:	$5	$10

Condensed_Balance_Sheets_Paren

Condensed Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Preferred stock shares authorized	100,000,000	100,000,000
Common stock par value	$0.00	$0.00
Common stock shares authorized	500,000,000	500,000,000
Common stock shares issued	29,306,026	29,046,386
Common stock shares outstanding	29,306,026	29,046,386
Series B Preferred Stock
Preferred stock shares authorized	5,000	5,000
Preferred stock par value	$0.00	$0.00
Preferred stock shares issued	5,000	5,000
Preferred stock shares outstanding	5,000	5,000
Series D preferred stock
Preferred stock shares authorized	200,000	200,000
Preferred stock par value	$0.00	$0.00
Preferred stock shares issued	50,000	200,000
Preferred stock shares outstanding	50,000	200,000
Series E preferred stock
Preferred stock shares authorized	100,000	100,000
Preferred stock par value	$0.00	$0.00
Preferred stock shares issued	45,000	100,000
Preferred stock shares outstanding	45,000	100,000

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Revenues
Gross charges (net of contractual allowances and discounts)	$20,122,515	$21,062,572
Provision for bad debts	-6,473,733	-6,187,033
Net Revenues	13,648,782	14,875,539
Operating expenses:
Direct costs of revenue	4,031,274	3,277,841
General and administrative	5,639,933	3,719,958
Legal fees related to disputed subsidiary	0	58,672
Sales and marketing expenses	1,182,221	789,302
Depreciation and amortization	580,793	165,688
Total operating expenses	11,434,221	8,011,461
Income from operations	2,214,561	6,864,078
Other income (expense):
Other income	21	121
Gain on disposition of subsidiary	0	134,185
Gain on legal settlement	275,028	0
Interest expense	-505,101	-96,751
Total other income (expense)	-230,052	37,555
Income before income taxes	1,984,509	6,901,633
Provision for income taxes	977,500	2,598,100
Net income attributable to Medytox Solutions	1,007,009	4,303,533
Preferred stock dividends	523,050	913,563
Net income (loss) attributable to Medytox Solutions common shareholders	$483,959	$3,389,970
Net income per common share: Basic	$0.02	$0.11
Net income per common share: Diluted	$0.02	$0.11
Weighted average number of shares outstanding during the period - Basic	29,141,679	30,043,053
Weighted average number of shares outstanding during the period - Diluted	31,269,912	30,337,497

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net income	$1,007,009	$4,303,533
Adjustments to reconcile net income to net cash provided by operations:
Depreciation and amortization	580,793	165,688
Stock issued in lieu of cash compensation	300,000	0
Stock-based compensation	56,463	0
Bad debts	6,473,733	6,187,033
Accretion of beneficial conversion feature as interest	246,575	3,278
Accretion of debt discount	93,699	0
Gain on disposition of subsidiary	0	-134,185
Gain on legal settlement	-275,028	0
Changes in operating assets and liabilities:
Accounts receivable	-12,843,394	-11,069,300
Prepaid expenses and other current assets	-16,935	-62,261
Deferred tax assets	0	-1,331,400
Security deposits	-39,222	-25,820
Accounts payable	-299,697	78,767
Accrued expenses	417,102	-115,891
Income tax liabilities	457,769	3,333,598
Deferred tax liabilities	48,900	33,000
Net cash provided by (used in) operating activities	-3,791,233	1,366,040
Cash flows used in investing activities:
Purchase of property and equipment	-213,142	-387,407
Cash paid for acquisitions	0	-1,000,000
Cash received in acquisitions	0	19,306
Net cash provided by (used in) investing activities	-213,142	-1,368,101
Cash flows provided by (used in) financing activities:
Dividends on Series B preferred stock	-523,050	-913,563
Proceeds from issuance of notes payable, related party	3,030,000	0
Payments on notes payable	-60,000	-429,486
Payments on capital lease obligations	-197,316	-57,093
Net cash provided by (used in) financing activities	2,249,634	-1,400,142
Net increase (decrease) in cash	-1,755,741	-1,402,203
Cash at beginning of period	2,406,246	4,141,416
Cash at end of period	650,505	2,739,213
Supplemental disclosure of cash flow information:
Cash paid for interest	160,835	85,951
Cash paid for taxes	470,831	600,000
Non-cash investing and financing activities:
Net liabilities (assets) acquired in acquisitions, net of cash	0	969,486
Goodwill	0	-2,273,503
Contingent acquisition liability	0	54,017
Notes payable issued	0	0
Series D preferred stock	0	20
Additional paid in capital	0	1,249,980
Adjustment to purchase price for Biohealth Medical Laboratory, Inc.:
Goodwill	259,875	0
Notes payable issued	-138,871	0
Accrued expenses	-121,004	0
Common stock issued as payment of accrued bonuses:
Accrued bonuses	0	-525,000
Common stock	0	21
Additional paid in capital	0	524,979
Capital lease assets acquired	0	-249,111
Capital lease obligations	$0	$249,111

1_Organization_and_Presentatio

1. Organization and Presentation	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
1. Organization and Presentation	Organization
	Medytox Solutions, Inc. (the “Company”), was incorporated in Nevada on July 20, 2005 as Casino Players, Inc. In the first half of 2011, Company management decided to reorganize the operations of the Company as a holding company to acquire and manage a number of companies in the medical services sector.
	On June 22, 2011, the Company organized Medytox Medical Management Solutions Corp. ("MMMSC"), a Florida corporation, as a wholly-owned subsidiary. MMMSC was a marketing company selling laboratory testing services to medical clinics, hospitals and physicians’ offices. On October 26, 2013, MMMSC changed its name to Medytox Information Technology, Inc. (“MIT”). MIT provides information technology services and solutions to all subsidiaries and customers of the Company and operates from the corporate offices in West Palm Beach, Florida.
	On July 26, 2011, the Company organized Medytox Institute of Laboratory Medicine, Inc. ("MILM"), a Florida corporation, as a wholly-owned subsidiary. MILM was organized to acquire and manage medical testing laboratories. MILM operates from the corporate offices in West Palm Beach, Florida.
	On August 22, 2011, the Company acquired 100% of the equity interests in Medical Billing Choices, Inc. ("MBC"), a privately-owned North Carolina corporation, through a stock purchase agreement for cash and an installment note. MBC operates a medical billing service for a variety of medical providers throughout the southeastern United States from offices in Charlotte, North Carolina. Since the acquisition, MBC is the main billing company for the Company's laboratories.
	On February 6, 2012, the Company formed Medytox Diagnostics Inc. (“MDI”), a Florida corporation, as a wholly-owned subsidiary to acquire and build clinical laboratories. MDI operates from the corporate offices in West Palm Beach, Florida.
	On February 16, 2012, MDI acquired majority interest in Collectaway LLC, now known as PB Laboratories, LLC ("PB Labs"), a Florida limited liability company. On October 12, 2012, MDI acquired the remaining controlling interest in PB Labs.  As of October 31, 2012, PB Labs is a wholly-owned subsidiary of MDI.
	On March 9, 2012, the Company formed Medytox Medical Marketing & Sales, Inc. (“MMMS”), a Florida corporation, as a wholly-owned subsidiary that provides marketing for clinical laboratories that are owned by the Company.
	On December 7, 2012, MDI acquired a majority interest in Biohealth Medical Laboratory, Inc. (“Biohealth”), a Florida corporation. The remaining minority interest was acquired on March 31, 2015. The initial agreement allowed MDI to retain all revenues.
	On January 1, 2013, MDI purchased 100% of the stock of Alethea Laboratories, Inc. ("Alethea"). Althea operates a licensed clinical lab in Las Cruces, New Mexico and is an enrolled Medicare provider.
	On January 29, 2013, MDI formed Advantage Reference Labs, Inc. (“Advantage”), a Florida corporation, as a wholly-owned subsidiary to provide reference, confirmation and clinical testing services. On October 14, 2013, Advantage changed its name to EPIC Reference Labs, Inc. (“EPIC”).
	On April 4, 2013, MDI purchased 100% of the interests in International Technologies, LLC ("Tech").  In October 2013, Tech began doing business as NJ Reference Labs (“NJ Ref”). NJ Ref operates a licensed clinical lab in Waldwick, New Jersey and is an enrolled Medicare provider.
	On March 18, 2014, MDI, purchased all of the outstanding stock of Clinlab, Inc. Clinlab develops and markets laboratory information management systems.
	On May 9, 2014, the Company formed Medical Mime, Inc. (“Mime”), a Florida corporation, as a wholly-owned subsidiary.
	On May 23, 2014, Mime purchased certain net assets, primarily consisting of software, of GlobalOne Information Technologies, LLC (“GlobalOne”). GlobalOne developed software and provided services for the electronic health records management (“ERMEHR”) segment of the medical industry.
	On July 28, 2014, the Company formed Platinum Financial Solutions, Ltd (“PFS”) as a 100% owned foreign subsidiary of the Company to pursue the opportunity of providing financial solutions, including factoring and accounts receivable acquisition in the healthcare sector. PFS has a Florida subsidiary, Platinum Financial Solutions, LLC, through which it may do business with U.S. based customers.
	On August 26, 2014, MDI purchased all of the outstanding stock of Epinex Diagnostics Laboratories, Inc. (“Epinex”), a California corporation. Epinex is a clinical laboratory in Tustin, California.
	Basis of Presentation
	The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial statement presentation and in accordance with Form 10-Q. Accordingly, they do not include all of the information and footnotes required in annual financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements contain all adjustments (consisting only of normal recurring accruals) necessary to present fairly the financial position and results of operations and cash flows for the interim periods reported in this Form 10-Q. The results of operations presented are not necessarily indicative of the results to be expected for any other interim period or for the entire year.
	These unaudited interim condensed consolidated financial statements should be read in conjunction with the 2014 audited annual financial statements included in the Annual Report on Form 10-K, filed with the U.S. Securities and Exchange Commission (“SEC”) on April 15, 2015.
	Revenue Recognition
	Service revenues are principally generated from laboratory testing services including chemical diagnostic tests such as blood analysis and urine analysis. Net service revenues are recognized at the time the testing services are performed and are reported at their estimated net realizable amounts.
	Net service revenues are determined utilizing gross service revenues net of contractual allowances. Even though it is the responsibility of the patient to pay for laboratory service bills, most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or a commercial insurance provider to pay all or a portion of their healthcare expenses; the majority of services provided by Medytox are to patients covered under a third party payor contract. In certain cases, the individual has no insurance or does not provide insurance information. Despite follow up billing efforts, the Company does not currently anticipate collection of a significant portion of self-pay billings including the patient responsibility portion of the billing for patients covered by third party payors. The Company currently does not have any capitated agreements. In the remainder of the cases, Medytox is provided the third party billing information and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like Medytox. Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and providing coverage (reimbursement) for specific tests. Estimated revenues are established based on a series of procedures and judgments that require industry specific healthcare experience and an understanding of payor methods and trends.
	We review our calculations on a monthly basis in order to make certain that we are properly allowing for the uncollectable portion of our gross billings and that our estimates remain sensitive to variances and changes within our payor groups. The contractual allowance calculation is made on the basis of historical allowance rates for the various specific payor groups on a monthly basis with a greater weight being given to the most recent trends; this process is adjusted based on recent changes in underlying contract provisions and shifts in the testing being performed. The provision for bad debts represents our estimate of net revenues that will ultimately be uncollectable and is based upon our analysis of historical payment rates by specific payor groups on a monthly basis with primary weight being given to the most recent trends; this approach allows bad debt to more accurately adjust to short-term changes in the business environment. These two calculations are routinely analyzed by Medytox on the basis of actual allowances issued by payors and the actual payments made to determine what adjustments, if any, are needed.
	Contractual Allowances and Doubtful Accounts
	Accounts receivable are reported at realizable value, net of allowances for contractual credits and doubtful accounts, which are estimated and recorded in the period the related revenue is recorded. The Company has a standardized approach to estimate and review the collectability of its receivables based on a number of factors, including the period they have been outstanding. Historical collection and payer reimbursement experience is an integral part of the estimation process related to allowances for contractual credits and doubtful accounts. In addition, the Company regularly assesses the state of its billing operations in order to identify issues which may impact the collectability of these receivables or reserve estimates. Receivables deemed to be uncollectible are charged against the allowance for doubtful accounts at the time such receivables are written-off. Recoveries of receivables previously written-off are recorded as credits to the allowance for doubtful accounts. Historically, revisions to the allowances for doubtful accounts estimates were recorded as an adjustment to the provision for bad debt within selling, general and administrative expenses.
	During the third quarter of 2014, the Company corrected the classification of the provision for bad debts from a component of operating expenses to a reduction in revenues in our Condensed Consolidated Statements of Operations. This presentation is required under U.S. GAAP due to the uncertainties of collection of the self-pay portion of patent service revenues.
	Basic and Diluted Income per Share
	The Company computes income per share in accordance with ASC 260, "Earnings per Share", which requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the statement of operations. Basic EPS is computed by dividing income available to common shareholders by the weighted average number of shares outstanding during the period. Diluted EPS gives effect to all potential dilutive equivalent shares of common stock outstanding during the period using the treasury stock method and convertible debt and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options, convertible debt, convertible preferred stock, or warrants.
	Segment Information
	In accordance with the provisions of ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”, the Company is required to report financial and descriptive information about its reportable operating segments. The Company has two operating segments; laboratory services and medical solutions support services.
	Reclassifications
	Certain other items on the statement of operations for the three months ended March 31, 2014 and the statement of cash flows for the three months ended March 31, 2014 have been reclassified to conform to current period presentation.

2_LongLived_Assets

2. Long-Lived Assets	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Long-Lived Assets	Property and equipment at March 31, 2015 and December 31, 2014 consisted of the following:
		March 31,			December 31,
		2015			2014
	Medical equipment	$	922,552		$	896,641
	Equipment		504,967			396,551
	Equipment under capital leases (See Note 5 - Capital Lease Obligations)		4,024,449			4,024,449
	Furniture		412,725			333,316
	Leasehold improvements		1,673,405			1,665,501
	Vehicles		177,534			177,534
	Computer equipment		599,081			595,571
	Software		1,832,053			1,832,053
			10,146,766			9,921,616
	Less accumulated depreciation		(2,828,245	)		(2,243,493	)
	Property and equipment, net	$	7,318,521		$	7,678,123
	Depreciation of property and equipment was $580,793 and $165,688 for the three months ended March 31, 2015 and 2014, respectively.
	Management periodically reviews the valuation of long-lived assets for potential impairments. Management has not recognized an impairment of these assets to date, and does not anticipate any negative impact from known current business developments.

3_Notes_Payable

3. Notes Payable	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Notes Payable	The Company and its subsidiaries are party to a number of loans with affiliates and unrelated parties. At March 31, 2015 and December 31, 2014, notes payable consisted of the following:
		March 31,			December 31,
		2015			2014
	Acquisition convertible note No. 1 to former member of International Technologies, LLC in the amount of $250,000 at 5% interest and was due January 17, 2014.  The note was convertible into the Company's common stock at a ten percent (10%) discount to the average market price for the thirty days prior to conversion. The note is discounted for its unamortized beneficial conversion feature of $-0- and $1,639 at March 31, 2015 and December 31, 2014, respectively. See "Acquisition Convertible Notes" below.	$	–		$	250,000
	Loan payable to former shareholder of Epinex Diagnostic Laboratories, Inc. in the amount of $400,000, at 0% interest, with principal payments of $100,000 due in periodic installments from November 26, 2014 through February 26, 2016. Amount recorded is net of imputed discount of $13,316 at December 31, 2014.		226,684			286,684
			226,684			536,684
	Less current portion		(226,684	)		(443,292	)
	Notes payable, net of current portion	$	–		$	93,392
	Note Payable – Related Parties
		31-Mar-15
		Face Value			Put			Put		Debt			Net Value
		of Note			Discount			Premium		Discount			of Note
	Convertible debenture dated December 31, 2014 in the amount of $3,000,000 which bears interest at 10% and is due December 31, 2015. The note provides the lender the option to covert the note into the Company's common stock at a 25% discount to the average trading price (as defined in the note agreement) for the ten consecutive trading days prior to the conversion date. The note has been discounted by the value of warrants issuable upon conversion of $380,000 at December 31, 2014.  The note has also been discounted by the unamortized value of its put premium of $1,000,000, and increased by the put premium liability of $1,000,000, at December 31, 2014.	$	3,000,000		$	(753,425	)	$	1,000,000	$	(286,301	)	$	2,960,274
	Loan payable to Alcimede LLC in the amount of $3,000,000, at 6% interest, with one payment of $3,000,000, plus interest, due on February 2, 2016.	$	3,000,000			–			–		–		$	3,000,000
	Loan payable to Alcimede LLC, dated February 27, 2015. (Repaid on April 15, 2015)	$	30,000			–			–		–		$	30,000
		$	6,030,000		$	(753,425	)	$	1,000,000	$	(286,301	)	$	5,990,274
	TCA Global
	Under terms of the Senior Secured Revolving Credit Facility agreement with TCA Global Credit Master Fund, LP, originally signed May 12, 2012 and as subsequently amended, the Company executed an Amended and Restated Revolving Promissory Note, due January 15, 2014, in the amount of $3,025,000. The note was extended by the lender from January 15, 2014 to September 15, 2014. The borrowings under this facility were repaid in full on September 8, 2014.
	Acquisition Convertible Notes
	The Company filed actions against Reginald Samuels and Ralph Perricelli seeking, among other things, a declaration that the convertible debentures in the aggregate amount of $500,000 that the Company issued to Mr. Samuels and Mr. Perricelli as part of the consideration for the purchase of their interests in International Technologies, LLC are null and void.
	All litigation with Mr. Samuels was settled by the Company on December 8, 2014. Specifics of the settlement are confidential.
	The Company received a default judgement against Mr. Perricelli in January 2015, relieving the Company of its obligations under the convertible debenture. The note payable and related accrued interest were written off in January 2015, resulting in a “Gain on Legal Settlement” of $275,028.

4_Related_Party_Transactions

4. Related Party Transactions	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions	On February 27, 2015, the Company borrowed $30,000 from Alcimede LLC, of which our CEO is the sole manager. The loan was repaid on April 15, 2015.
	On February 3, 2015, the Company borrowed $3,000,000 from Alcimede LLC, of which our CEO is the sole manager. The note has an interest rate of 6% and is due on February 2, 2016.
	On December 31, 2014, the Company borrowed $3,000,000 from D&D Funding II, LLC (“D&D”), Christopher Diamantis, a director of the Company, is the manager and 50% owner of D&D. (See Note 3 for a description of this Note.)

5_Capital_Lease_Obligations

5. Capital Lease Obligations	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Capital Lease Obligations	The Company leases various assets under capital leases expiring through 2020 as follows:
		March 31,			December 31,
		2015			2014
	Medical equipment	$	4,024,449		$	4,024,449
	Less accumulated depreciation		(1,098,060	)		(883,015	)
	Net	$	2,926,389		$	3,141,434
	Depreciation expense on assets under capital leases was $215,045 and $54,980 for the three months ended March 31, 2015 and 2014, respectively.
	Aggregate future minimum rentals under capital leases are as follows:
	Future minimum rentals
	December 31,
	2015	$	846,860
	2016		1,078,010
	2017		969,606
	2018		382,395
	2019		35,575
	Thereafter		32,611
	Total		3,345,057
	Less interest		357,186
	Present value of minimum lease payments		2,987,871
	Less current portion of capital lease obligations		727,307
	Capital lease obligations, net of current portion	$	2,260,564

6_Stockholders_Equity

6. Stockholders' Equity

3 Months Ended

Mar. 31, 2015

Equity [Abstract]

Stockholders' Equity

Authorized Capital

The Company has 500,000,000 authorized shares of Common Stock at $0.0001 par value per share and 100,000,000 authorized shares of Preferred Stock at $0.0001 par value per share.

On October 1, 2012, the Company filed a certificate of designation with the Secretary of State of Nevada to designate 5,000 shares of Series B Non-convertible Preferred Stock, at $0.0001 par value per share.  The Series B shares do not include any voting rights and allow for monthly dividends in an amount equal to the sum of 1) 10% of the amount of gross sales in excess of $1 million collected in the ordinary course of business, not to exceed $150,000, and 2) 15% of the amount of gross sales in excess of $2.5 million collected in the ordinary course of business. At each of March 31, 2015 and December 31, 2014, there were 5,000 shares of Series B Preferred Stock outstanding.

On March 27, 2014, each of the holders of shares of Series B Preferred Stock entered into a purchase option agreement with the Company. Each agreement grants the Company an option to purchase any or all shares of Series B Preferred Stock held by the holder at any time through March 27, 2016 at a purchase price of $5,000 per share. Each holder agreed not to transfer or dispose of any shares of Series B Preferred Stock during the term of the option, other than to the Company upon an exercise of the option. Any exercise of an option is completely at the Company's discretion.

On October 7, 2012, the Company filed a certificate of designation with the Secretary of State of Nevada to designate 1,000,000 shares of Series C Convertible Preferred Stock, at $0.0001 par value per share. The Series C shares were convertible into shares of Common Stock by the quotient of 1 divided by the product of 0.80 multiplied by the market price of the Company’s Common Stock at the date of conversion. The Series C shares also included voting rights of 25 votes for every share of Series C Preferred Stock and were entitled to dividends at the same time any dividend was paid or declared on any shares of the Company’s Common Stock. Pursuant to their terms, all of the shares of Series C Preferred Stock were converted into shares of Common Stock on December 31, 2013.

On March 17, 2014, the Company filed a Certificate of Designation with the Secretary of State of Nevada authorizing up to 200,000 shares of Series D Convertible Preferred Stock at $0.0001 par value per share ("Series D Preferred Stock"). Each share of Series D Preferred Stock is convertible into the number of shares of Common Stock equal to the quotient of 5 divided by the product of 0.80 multiplied by the market price, as defined in Certificate of Designation, of the Company’s Common Stock at the date of conversion. After the earlier of the date the trading volume of the Common Stock exceeds an aggregate of 3,000,000 shares in any 30 day period or the date the Company sells shares of Common Stock in a firm commitment underwritten public offering with aggregate gross proceeds of at least $30,000,000, each share of Series D Preferred Stock shall be convertible into the number of shares of Common Stock equal to the quotient of (i) 5 divided by (ii) the market price of the Common Stock. All shares of Series D Preferred Stock outstanding on the second anniversary of the original issuance date shall be automatically converted into shares of Common Stock.

The Series D shares also include voting rights of 1 vote for every share of Series D Preferred Stock and are entitled to dividends, at the same time any dividend is paid or declared on any shares of the Company’s Common Stock The dividends are to be in an amount equal to the amount such holder would have received if the Series D Preferred Stock were converted to Common Stock. As of March 31, 2015 and December 31, 2014, there were 50,000 and 200,000 shares of Series D Preferred Stock outstanding, respectively.

On August 21, 2014, the Company filed a Certificate of Designation with the Secretary of State of Nevada authorizing 100,000 shares of Series E Convertible Preferred Stock at a par value of $.0001 per share. The Series E shares are convertible into the number of shares of Common Stock equal to the quotient of 8 divided by the average market price of the Company’s Common Stock for thirty trading days prior to the date of conversion, multiplied by the number of Series E shares being converted. Any Series E shares which remain outstanding on August 28, 2016 will be automatically converted into Common Stock using the prescribed formula. The Series E shares also include voting rights of 1 vote for every share of Series E Preferred Stock and are entitled to dividends at the same time any dividend is paid or declared on any shares of the Company’s Common Stock. The dividends are to be in an amount equal to the amount such holder would have received if the Series E Preferred Stock were converted to Common Stock at the same time any dividend is paid or declared on any shares of the Company’s Common Stock. As of March 31, 2015 and December 31, 2014, there were 45,000 and 100,000 shares of Series E Preferred Stock outstanding, respectively.

Preferred Stock

During the three months ended March 31, 2015 and 2014, the Series B preferred shareholders earned dividends totaling $523,050 and $913,563, respectively.

On March 18, 2014, 200,000 shares of Series D Preferred Stock of the Company were issued to the previous owners of Clinlab pursuant to a stock purchase agreement whereby the Company purchased all of the outstanding stock of Clinlab. On March 20, 2015, 150,000 shares of this Series D Preferred stock were converted into 125,334 shares of common stock.

On August 28, 2014, 100,000 shares of Series E Preferred Stock of the Company were issued to the previous owner of Epinex pursuant to a stock purchase agreement whereby the Company purchased all of the outstanding stock of Epinex. On March 3, 2015, 55,000 shares of this Series E Preferred stock were converted into 58,856 shares of common stock.

Common Stock

During the three months ended March 31, 2015 , the Company issued an aggregate of 259,190 shares of the Company’s common stock; 184,190 were issued in connection with the conversions of the Series D and E Preferred Stock and 75,000 shares, valued at $4.00 per share, were issued as compensation to two employees pursuant to employment agreements.

2013 Equity Plan

On September 25, 2013, the Company’s board of directors approved and adopted the Medytox Solutions, Inc. 2013 Incentive Compensation Plan (the “2013 Plan”). The 2013 Plan was approved by a majority of stockholders of the Company on November 22, 2013. The 2013 Plan provides for the grant of shares of common stock, options, performance shares, performance units, restricted stock, stock appreciation rights and other awards.

The following summarizes activity under the 2013 Plan through March 31, 2015:

Shares approved for issuance at plan inception

5,000,000

Options granted in 2014

(1,435,000

)

Options cancelled in 2014

10,000

Restricted shares issued in 2014

(210,000

)

Balance at December 31, 2014 and March 31, 2015

3,365,000

Stock Options

The following summarizes options outstanding at March 31, 2015:

Weighted

average

Options

exercise

Outstanding

price

Balance at March 31, 2015

24,225,000

$

5.47

The following table summarizes information with respect to stock options outstanding and exercisable by employees, directors and consultants at March 31, 2015:

Options outstanding

Options vested and exercisable

Weighted

average

Weighted

Weighted

remaining

average

Aggregate

average

Aggregate

Exercise

Number

contractual

exercise

intrinsic

Number

exercise

intrinsic

price

outstanding

life (years)

price

value

vested

price

value

$2.50

9,475,000

3.37

$2.50

$

14,212,500

8,987,500

$2.50

$

13,481,250

$5.00

7,750,000

2.99

$5.00

–

7,700,000

$5.00

–

$10.00

7,000,000

8.01

$10.00

–

7,000,000

$10.00

–

24,225,000

$5.47

$

14,212,500

23,687,500

$5.53

$

13,481,250

During the three months ended March 31, 2014, the Company issued options to purchase a total of 100,000 shares of the Company’s common stock to an employee pursuant to terms of an employment agreement. These options had contractual lives of two years and were valued at an average grant date fair value of $0.25 per option, or $25,000, using the Black-Scholes Option Pricing Model with the following assumptions:

Stock price

$2.50

Expected term

1 year

Expected volatility

24.43%

Risk free interest rate

0.30%

Dividend yield

0

The stock price was based on the price of shares sold to investors and volatility was based on comparable volatility of other companies since the Company had no significant historical volatility.

During the three months ended March 31, 2014, the Company issued options to purchase a total of 1,035,000 shares of the Company’s common stock to various employees. These options had contractual lives of ten years and were valued at an average grant date fair value of $0.70 per option, or $724,500, using the Black-Scholes Option Pricing Model with the following assumptions:

Stock price

$2.50

Expected term

5.375 years

Expected volatility

27.72%

Risk free interest rate

1.46%

Dividend yield

0

The stock price was based on the price of shares sold to investors and volatility was based on comparable volatility of other companies since the Company had no significant historical volatility. As of March 31, 2015, all of these options had vested and the Company recognized $52,024 of stock-based compensation expense for the three months ended March 31, 2015.

In May 2014, the Company issued options to purchase a total of 300,000 shares of the Company’s common stock to a director. These options had contractual lives of four years and were valued at an average grant date fair value of $0.18 per option, or $54,000, using the Black-Scholes Option Pricing Model with the following assumptions:

Stock price

$2.50

Expected term

2 years

Expected volatility

24.43%

Risk free interest rate

0.43%

Dividend yield

0

The stock price was based on the price of shares sold to investors and volatility was based on comparable volatility of other companies since the Company had no significant historical volatility. As of March 31, 2015, 200,000 of these options had vested and the Company recognized $4,438 of stock-based compensation expense for the three months ended March 31, 2015.

As of March 31, 2015, there were unrecognized compensation costs of $2,959 related to stock options. The Company expects to recognize those costs over a weighted average period of .16 years as of March 31, 2015. Future option grants will increase the amount of compensation expense to be recorded in these periods.

Warrants

The following table summarizes warrant transactions for the three months ended March 31, 2015:

Weighted

Weighted

average

average

remaining

Aggregate

Number

exercise

contractual

intrinsic

of warrants

price

term (years)

value

Outstanding and Exercisable at December 31, 2014

300,000

$

3.33

–

$

–

Outstanding and Exercisable at March 31, 2015

–

$

–

–

$

–

Weighted Average Grant Date Fair Value

$

–

The warrants were issued by the Company in 2013 to two individuals in connection with obligations entered into by the Company’s subsidiaries. These warrants had contractual lives of two years and expired in January 2015.

Basic and Diluted Income per Share

The Company computes income per share in accordance with ASC 260, "Earnings per Share", which requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the statement of operations. Basic EPS is computed by dividing income available to common shareholders by the weighted average number of shares outstanding during the period. Diluted EPS gives effect to all potential dilutive equivalent shares of common stock outstanding during the period using the treasury stock method and convertible debt and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options, convertible debt, convertible preferred stock, or warrants.

Basic and Diluted EPS were calculated as follows:

Three Months Ended March 31,

2015

2014

Basic:

Numerator - net income available to common stockholders

$

483,959

3,389,970

Denominator - weighted-average shares outstanding

29,141,679

30,043,053

Net income per share - Basic

$

0.02

$

0.11

Diluted:

Numerator:

Net income available to common stockholders

$

483,959

$

3,389,970

Interest expense on convertible debt, net of taxes

46,912

3,700

530,871

3,393,670

Denominator:

Weighted-average shares outstanding

29,141,679

30,043,053

Weighted-average equivalent shares options and warrants

866,378

–

Weighted-average equivalent shares from convertible debt

1,000,000

222,222

Weighted-average equivalent shares from Series C convertible preferred stock

–

–

Weighted-average equivalent shares from Series D convertible preferred stock

179,776

72,222

Weighted-average equivalent shares from Series E convertible preferred stock

82,079

–

31,269,912

30,337,497

Net income per share - Diluted

$

0.02

$

0.11

Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. As of March 31, 2015 and 2014, the following potential common stock equivalents were excluded from the calculation of Diluted EPS as their effect was anti-dilutive:

March 31,

2015

2014

Stock options outstanding

24,225,000

23,995,000

Warrants outstanding

–

346,400

24,225,000

24,341,400

7_Income_Taxes

7. Income Taxes	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Significant components of the income tax provision are summarized as follows:
		Three Months Ended March 31,
		2015			2014
	Current provision:
	Federal	$	792,900		$	3,327,000
	State		135,700			569,500
	Deferred provision:
	Federal		44,100			(1,173,200	)
	State		4,800			(125,200	)
		$	977,500		$	2,598,100
	A reconciliation of the statutory federal income tax rate to the Company’s effective income tax rate on income before income taxes for the three months ended March 31, 2015 and 2014 is as follows:
		Three Months Ended March 31,
		2015			2014
	Expected federal income tax at 34% statutory rate		34.00%			34.00%
	State income taxes		4.70%			4.20%
	Permanent differences		10.60%			-0.60%
			49.30%			37.60%
	Of the $8,545,715 of income tax liabilities at March 31, 2015, $1,649,877 relates to 2013 and $5,967,238 relates to 2014. The Company has made no payments on its 2015 tax liability.
	The Company provides for income taxes using the liability method in accordance with FASB ASC Topic 740 “Income Taxes”. Deferred income taxes arise from the differences in the recognition of income and expenses for tax purposes. Deferred tax assets and liabilities are comprised of the following at March 31, 2015 and December 31, 2014:
		March 31,			December 31,
		2015			2014
	Deferred income tax assets:
	Allowance for bad debts	$	28,300		$	28,300
	Stock options		444,400			423,200
	Total deferred income tax assets	$	472,700		$	451,500
	Deferred income tax liabilities:
	Property and equipment	$	(558,800	)	$	(513,600	)
	Intangible amortization		(187,400	)		(162,500	)
	Total deferred income tax liabilities	$	(746,200	)	$	(676,100	)
	Net deferred income taxes:
	Current	$	28,300		$	28,300
	Non-current		(301,800	)		(252,900	)
		$	(273,500	)	$	(224,600	)
	Management has reviewed the provisions regarding assessment of its valuation allowance on deferred tax assets and based on that criteria determined that it will have sufficient taxable income to realize those assets. Therefore, management has assessed the realization of the deferred tax assets and has determined that it is more likely than not that they will be realized.
	The Company recognizes the consolidated financial statement impact of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than–not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.

8_Business_Combinations

8. Business Combinations	3 Months Ended
	Mar. 31, 2015
Business Combinations [Abstract]
Business Combinations	The Company acquired the remaining 49.5% of Biohealth in the three months ended March 31, 2015. The Company completed three acquisitions during the year ended December 31, 2014. The Company accounted for the assets, liabilities and ownership interests in accordance with the provisions of FASB ASC 805 “Business Combinations”. As such, the recorded assets and liabilities acquired have been recorded at fair value and any difference in the net asset values and the consideration given has been recorded as goodwill.
	Goodwill was attributable to the following subsidiaries as of March 31, 2015 and December 31, 2014:
		March 31,		December 31,
		2015		2014
	Medical Billing Choices, Inc.	$	1,202,112	$	1,202,112
	PB Laboratories, LLC		107,124		107,124
	Biohealth Medical Laboratory, Inc.		255,634		116,763
	Clinlab, Inc.		857,532		857,532
	Medical Mime, Inc.		274,811		274,811
	Epinex Diagnostics Laboratories, Inc.		581,600		581,600
		$	3,278,813	$	3,139,942
	The purchase of the remaining portion of Biohealth increased previously reported goodwill by $138,871.
	On January 16, 2015, in contemplation of the business combination the Company entered into a Loan and Security Agreement with CollabRx, Inc. (“CollabRx”), pursuant to which it was agreed the Company would loan up to $2,395,644 to CollabRx and an Agreement with CollabRx, pursuant to which CollabRx agreed that in the event it enters into a merger or other sale transaction involving at least thirty-five percent (35.0%) of its shares or assets with a party other than the Company, CollabRx will pay the Company a $1,000,000 fee.
	On February 19, 2015, Medytox and CollabRx entered into an amendment to the Loan Agreement. The Amendment sets forth CollabRx’s agreement not to request any further advances from Medytox pursuant to the Loan Agreement until after it has spent at least the greater of (i) $1,500,000 of the proceeds of a recent offering by CollabRx of shares of its common stock and warrants or (ii) 60% of the net proceeds of the offering.
	All amounts loaned to date under the Loan Agreement were repaid during the three months ended March 31, 2015. (See further discussion of the contemplated CollabRx acquisition in Note 11)

9_Commitments_and_Contingencie

9. Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Legal Matters
	During the course of business, litigation commonly occurs.  From time to time the Company may be a party to litigation matters involving claims against the Company. The Company operates in a highly regulated industry and employs personnel which may inherently lend itself to legal matters.  Management is aware that litigation has associated costs and that results of adverse litigation verdicts could have a material effect on the Company's financial position or results of operations. Management, in consultation with legal counsel, has addressed known assertions and unasserted claims below.
	On February 26, 2014, the Company filed an action against Reginald Samuels and Ralph Perricelli in the United States District Court for the Southern District of Florida seeking, among other things, a declaration that the convertible debentures in the aggregate amount of $500,000 that the Company issued to Mr. Samuels and Mr. Perricelli as part of the consideration for the purchase of their interests in International Technologies, LLC are null and void.  On October 21, 2013, Mr. Samuels had filed a complaint in the Superior Court of New Jersey (Bergen County) against the Company and Medytox Diagnostics, Inc. alleging breach of contract under his employment agreement and the agreement under which International Technologies, LLC was acquired; unjust enrichment, fraud; intentional and negligent misrepresentation; and breach of an implied duty of good faith and fair dealing and seeking an accounting.  Mr. Perricelli filed a similar action.
	All litigation with Reginald Samuels was settled by the Company on December 8, 2014. Specifics of the settlement are confidential.
	The Company received a default judgement against Ralph Perricelli on February 12, 2015, relieving the Company of its obligations under the convertible debenture. As a consequence of the settlement, the Company recognized a gain of $275,028.

10_Segment_Reporting

10. Segment Reporting	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Segment Reporting	Selected financial information for the Company’s operating segments is as follows:
		Three Months Ended March 31,
		2015			2014
	Net revenues - External
	Laboratory Services	$	13,499,803		$	14,788,210
	Medical Support Solutions		148,979			87,329
	Corporate & Eliminations		–			–
		$	13,648,782		$	14,875,539
	Net revenues - Inter Segment
	Laboratory Services	$	–		$	–
	Medical Support Solutions		384,108			516,744
	Corporate & Eliminations		–			–
		$	384,108		$	516,744
	Income (loss) from operations
	Laboratory Services	$	5,065,421		$	7,277,346
	Medical Support Solutions		(1,357,989	)		103,476
	Corporate & Eliminations		(1,492,870	)		(516,744	)
		$	2,214,562		$	6,864,078
	Depreciation and amortization
	Laboratory Services	$	447,325		$	156,690
	Medical Support Solutions		160,356			8,998
	Corporate & Eliminations		(26,888	)		–
		$	580,793		$	165,688
	Capital expenditures
	Laboratory Services	$	187,885		$	279,381
	Medical Support Solutions		25,257			108,026
	Corporate & Eliminations		–			–
		$	213,142		$	387,407
		March 31,			December 31,
		2015			2014
	Total assets
	Laboratory Services	$	35,191,475		$	29,362,062
	Medical Support Solutions		6,330,406			5,214,139
	Corporate & Eliminations		(1,579,705	)		1,184,553
		$	39,942,176		$	35,760,754
	Intangible assets
	Laboratory Services	$	4,087,502		$	4,088,835
	Medical Support Solutions		340,922			347,638
	Corporate & Eliminations		–			–
		$	4,428,424		$	4,436,473
	Goodwill
	Laboratory Services	$	944,358		$	805,487
	Medical Support Solutions		2,334,455			2,334,455
	Corporate & Eliminations		–			–
		$	3,278,813		$	3,139,942

11_Subsequent_Events

11. Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	On April 15, 2015, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among Medytox, CollabRx, and CollabRx Merger Sub, Inc., a wholly owned subsidiary of CollabRx (“Merger Sub”), pursuant to which it is contemplated that Merger Sub would merge with and into Medytox, with Medytox surviving the merger as a wholly owned subsidiary of CollabRx (the “Merger”).
	In the Merger, (i) each share of Medytox Common Stock will be converted into the right to receive such number of shares of CollabRx Common Stock equal to the Exchange Ratio (as defined in the Merger Agreement), (ii) each share of Medytox Series B Preferred Stock will be converted into the right to receive one share of CollabRx Series B Preferred Stock, which will be designated prior to the closing of the Merger, (iii) each share of Medytox Series D Preferred Stock will be converted into the right to receive one share of CollabRx Series D Preferred Stock, which will be designated prior to the closing of the Merger, (iv) each share of Medytox Series E Preferred Stock will be converted into the right to receive one share of CollabRx Series E Preferred Stock, which will be designated prior to the closing of the Merger, (v) each option and warrant to purchase shares of CollabRx Common Stock will continue in existence pursuant to its terms, (vi) each restricted stock unit for CollabRx Common Stock will settle prior to the closing of the Merger in accordance with its terms, and (vii) Medytox’s equity incentive plan will be assumed by CollabRx and each outstanding option to purchase shares of Medytox Common Stock will be assumed by CollabRx and converted into an option to purchase shares of CollabRx Common Stock (with proportional adjustment to the number of shares underlying the option and the exercise price, each in accordance with the Exchange Ratio). The Exchange Ratio will be calculated such that holders of CollabRx equity prior to the closing of the Merger (including all outstanding CollabRx Common Stock and all restricted stock units, options and warrants exercisable for shares of CollabRx Common Stock) will hold 10% of CollabRx’s Common Stock following the closing of the Merger, and holders of Medytox equity prior to the closing of the Merger (including all outstanding Medytox Common Stock and all outstanding options exercisable for shares of Medytox Common Stock, but less certain options that will be cancelled contingent upon the closing pursuant to agreements between Medytox and such optionees) will hold 90% of CollabRx’s Common Stock following the closing of the Merger, in each case on a fully diluted basis, provided, however, outstanding shares of the newly designated CollabRx Series B Preferred Stock, Series D Preferred Stock and Series E Preferred Stock, certain outstanding convertible promissory notes exercisable for CollabRx Common Stock after the closing and certain option grants expected to be made at or immediately following the closing of the Merger are excluded from such ownership percentages.
	The Company has evaluated other subsequent events through the date the financial statements were issued and filed with the SEC. The Company has determined that there are no other subsequent events that warrant disclosure or recognition in the consolidated financial statements.

1_Organization_and_Presentatio1

1. Organization and Presentation (Policies)	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	Organization
	Medytox Solutions, Inc. (the “Company”), was incorporated in Nevada on July 20, 2005 as Casino Players, Inc. In the first half of 2011, Company management decided to reorganize the operations of the Company as a holding company to acquire and manage a number of companies in the medical services sector.
	On June 22, 2011, the Company organized Medytox Medical Management Solutions Corp. ("MMMSC"), a Florida corporation, as a wholly-owned subsidiary. MMMSC was a marketing company selling laboratory testing services to medical clinics, hospitals and physicians’ offices. On October 26, 2013, MMMSC changed its name to Medytox Information Technology, Inc. (“MIT”). MIT provides information technology services and solutions to all subsidiaries and customers of the Company and operates from the corporate offices in West Palm Beach, Florida.
	On July 26, 2011, the Company organized Medytox Institute of Laboratory Medicine, Inc. ("MILM"), a Florida corporation, as a wholly-owned subsidiary. MILM was organized to acquire and manage medical testing laboratories. MILM operates from the corporate offices in West Palm Beach, Florida.
	On August 22, 2011, the Company acquired 100% of the equity interests in Medical Billing Choices, Inc. ("MBC"), a privately-owned North Carolina corporation, through a stock purchase agreement for cash and an installment note. MBC operates a medical billing service for a variety of medical providers throughout the southeastern United States from offices in Charlotte, North Carolina. Since the acquisition, MBC is the main billing company for the Company's laboratories.
	On February 6, 2012, the Company formed Medytox Diagnostics Inc. (“MDI”), a Florida corporation, as a wholly-owned subsidiary to acquire and build clinical laboratories. MDI operates from the corporate offices in West Palm Beach, Florida.
	On February 16, 2012, MDI acquired majority interest in Collectaway LLC, now known as PB Laboratories, LLC ("PB Labs"), a Florida limited liability company. On October 12, 2012, MDI acquired the remaining controlling interest in PB Labs.  As of October 31, 2012, PB Labs is a wholly-owned subsidiary of MDI.
	On March 9, 2012, the Company formed Medytox Medical Marketing & Sales, Inc. (“MMMS”), a Florida corporation, as a wholly-owned subsidiary that provides marketing for clinical laboratories that are owned by the Company.
	On December 7, 2012, MDI acquired a majority interest in Biohealth Medical Laboratory, Inc. (“Biohealth”), a Florida corporation. The remaining minority interest was acquired on March 31, 2015. The initial agreement allowed MDI to retain all revenues.
	On January 1, 2013, MDI purchased 100% of the stock of Alethea Laboratories, Inc. ("Alethea"). Althea operates a licensed clinical lab in Las Cruces, New Mexico and is an enrolled Medicare provider.
	On January 29, 2013, MDI formed Advantage Reference Labs, Inc. (“Advantage”), a Florida corporation, as a wholly-owned subsidiary to provide reference, confirmation and clinical testing services. On October 14, 2013, Advantage changed its name to EPIC Reference Labs, Inc. (“EPIC”).
	On April 4, 2013, MDI purchased 100% of the interests in International Technologies, LLC ("Tech").  In October 2013, Tech began doing business as NJ Reference Labs (“NJ Ref”). NJ Ref operates a licensed clinical lab in Waldwick, New Jersey and is an enrolled Medicare provider.
	On March 18, 2014, MDI, purchased all of the outstanding stock of Clinlab, Inc. Clinlab develops and markets laboratory information management systems.
	On May 9, 2014, the Company formed Medical Mime, Inc. (“Mime”), a Florida corporation, as a wholly-owned subsidiary.
	On May 23, 2014, Mime purchased certain net assets, primarily consisting of software, of GlobalOne Information Technologies, LLC (“GlobalOne”). GlobalOne developed software and provided services for the electronic health records management (“ERMEHR”) segment of the medical industry.
	On July 28, 2014, the Company formed Platinum Financial Solutions, Ltd (“PFS”) as a 100% owned foreign subsidiary of the Company to pursue the opportunity of providing financial solutions, including factoring and accounts receivable acquisition in the healthcare sector. PFS has a Florida subsidiary, Platinum Financial Solutions, LLC, through which it may do business with U.S. based customers.
	On August 26, 2014, MDI purchased all of the outstanding stock of Epinex Diagnostics Laboratories, Inc. (“Epinex”), a California corporation. Epinex is a clinical laboratory in Tustin, California.
Basis of Presentation	Basis of Presentation
	The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial statement presentation and in accordance with Form 10-Q. Accordingly, they do not include all of the information and footnotes required in annual financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements contain all adjustments (consisting only of normal recurring accruals) necessary to present fairly the financial position and results of operations and cash flows for the interim periods reported in this Form 10-Q. The results of operations presented are not necessarily indicative of the results to be expected for any other interim period or for the entire year.
	These unaudited interim condensed consolidated financial statements should be read in conjunction with the 2014 audited annual financial statements included in the Annual Report on Form 10-K, filed with the U.S. Securities and Exchange Commission (“SEC”) on April 15, 2015.
Revenue Recognition	Revenue Recognition
	Service revenues are principally generated from laboratory testing services including chemical diagnostic tests such as blood analysis and urine analysis. Net service revenues are recognized at the time the testing services are performed and are reported at their estimated net realizable amounts.
	Net service revenues are determined utilizing gross service revenues net of contractual allowances. Even though it is the responsibility of the patient to pay for laboratory service bills, most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or a commercial insurance provider to pay all or a portion of their healthcare expenses; the majority of services provided by Medytox are to patients covered under a third party payor contract. In certain cases, the individual has no insurance or does not provide insurance information. Despite follow up billing efforts, the Company does not currently anticipate collection of a significant portion of self-pay billings including the patient responsibility portion of the billing for patients covered by third party payors. The Company currently does not have any capitated agreements. In the remainder of the cases, Medytox is provided the third party billing information and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like Medytox. Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and providing coverage (reimbursement) for specific tests. Estimated revenues are established based on a series of procedures and judgments that require industry specific healthcare experience and an understanding of payor methods and trends.
	We review our calculations on a monthly basis in order to make certain that we are properly allowing for the uncollectable portion of our gross billings and that our estimates remain sensitive to variances and changes within our payor groups. The contractual allowance calculation is made on the basis of historical allowance rates for the various specific payor groups on a monthly basis with a greater weight being given to the most recent trends; this process is adjusted based on recent changes in underlying contract provisions and shifts in the testing being performed. The provision for bad debts represents our estimate of net revenues that will ultimately be uncollectable and is based upon our analysis of historical payment rates by specific payor groups on a monthly basis with primary weight being given to the most recent trends; this approach allows bad debt to more accurately adjust to short-term changes in the business environment. These two calculations are routinely analyzed by Medytox on the basis of actual allowances issued by payors and the actual payments made to determine what adjustments, if any, are needed.
Contractual Allowances and Doubtful Accounts	Contractual Allowances and Doubtful Accounts
	Accounts receivable are reported at realizable value, net of allowances for contractual credits and doubtful accounts, which are estimated and recorded in the period the related revenue is recorded. The Company has a standardized approach to estimate and review the collectability of its receivables based on a number of factors, including the period they have been outstanding. Historical collection and payer reimbursement experience is an integral part of the estimation process related to allowances for contractual credits and doubtful accounts. In addition, the Company regularly assesses the state of its billing operations in order to identify issues which may impact the collectability of these receivables or reserve estimates. Receivables deemed to be uncollectible are charged against the allowance for doubtful accounts at the time such receivables are written-off. Recoveries of receivables previously written-off are recorded as credits to the allowance for doubtful accounts. Historically, revisions to the allowances for doubtful accounts estimates were recorded as an adjustment to the provision for bad debt within selling, general and administrative expenses.
	During the third quarter of 2014, the Company corrected the classification of the provision for bad debts from a component of operating expenses to a reduction in revenues in our Condensed Consolidated Statements of Operations. This presentation is required under U.S. GAAP due to the uncertainties of collection of the self-pay portion of patent service revenues.
Basic and Diluted Income per Share	Basic and Diluted Income per Share
	The Company computes income per share in accordance with ASC 260, "Earnings per Share", which requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the statement of operations. Basic EPS is computed by dividing income available to common shareholders by the weighted average number of shares outstanding during the period. Diluted EPS gives effect to all potential dilutive equivalent shares of common stock outstanding during the period using the treasury stock method and convertible debt and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options, convertible debt, convertible preferred stock, or warrants.
Segment Information	Segment Information
	In accordance with the provisions of ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”, the Company is required to report financial and descriptive information about its reportable operating segments. The Company has two operating segments; laboratory services and medical solutions support services.
Reclassifications	Reclassifications
	Certain other items on the statement of operations for the three months ended March 31, 2014 and the statement of cash flows for the three months ended March 31, 2014 have been reclassified to conform to current period presentation.

2_LongLived_Assets_Tables

2. Long-Lived Assets (Tables)	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Property and equipment		March 31,			December 31,
		2015			2014
	Medical equipment	$	922,552		$	896,641
	Equipment		504,967			396,551
	Equipment under capital leases (See Note 5 - Capital Lease Obligations)		4,024,449			4,024,449
	Furniture		412,725			333,316
	Leasehold improvements		1,673,405			1,665,501
	Vehicles		177,534			177,534
	Computer equipment		599,081			595,571
	Software		1,832,053			1,832,053
			10,146,766			9,921,616
	Less accumulated depreciation		(2,828,245	)		(2,243,493	)
	Property and equipment, net	$	7,318,521		$	7,678,123

3_Notes_Payable_Tables

3. Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Schedule of Notes Payable		March 31,			December 31,
		2015			2014
	Acquisition convertible note No. 1 to former member of International Technologies, LLC in the amount of $250,000 at 5% interest and was due January 17, 2014.  The note was convertible into the Company's common stock at a ten percent (10%) discount to the average market price for the thirty days prior to conversion. The note is discounted for its unamortized beneficial conversion feature of $-0- and $1,639 at March 31, 2015 and December 31, 2014, respectively. See "Acquisition Convertible Notes" below.	$	–		$	250,000
	Loan payable to former shareholder of Epinex Diagnostic Laboratories, Inc. in the amount of $400,000, at 0% interest, with principal payments of $100,000 due in periodic installments from November 26, 2014 through February 26, 2016. Amount recorded is net of imputed discount of $13,316 at December 31, 2014.		226,684			286,684
			226,684			536,684
	Less current portion		(226,684	)		(443,292	)
	Notes payable, net of current portion	$	–		$	93,392
Notes Payable - Related Parties		31-Mar-15
		Face Value			Put			Put		Debt			Net Value
		of Note			Discount			Premium		Discount			of Note
	Convertible debenture dated December 31, 2014 in the amount of $3,000,000 which bears interest at 10% and is due December 31, 2015. The note provides the lender the option to covert the note into the Company's common stock at a 25% discount to the average trading price (as defined in the note agreement) for the ten consecutive trading days prior to the conversion date. The note has been discounted by the value of warrants issuable upon conversion of $380,000 at December 31, 2014.  The note has also been discounted by the unamortized value of its put premium of $1,000,000, and increased by the put premium liability of $1,000,000, at December 31, 2014.	$	3,000,000		$	(753,425	)	$	1,000,000	$	(286,301	)	$	2,960,274
	Loan payable to Alcimede LLC in the amount of $3,000,000, at 6% interest, with one payment of $3,000,000, plus interest, due on February 2, 2016.	$	3,000,000			–			–		–		$	3,000,000
	Loan payable to Alcimede LLC, dated February 27, 2015. (Repaid on April 15, 2015)	$	30,000			–			–		–		$	30,000
		$	6,030,000		$	(753,425	)	$	1,000,000	$	(286,301	)	$	5,990,274

5_Capital_Lease_Obligations_Ta

5. Capital Lease Obligations (Tables)	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Capital Lease table		March 31,			December 31,
		2015			2014
	Medical equipment	$	4,024,449		$	4,024,449
	Less accumulated depreciation		(1,098,060	)		(883,015	)
	Net	$	2,926,389		$	3,141,434
Aggregate future minimum rentals under capital leases	December 31,
	2015	$	846,860
	2016		1,078,010
	2017		969,606
	2018		382,395
	2019		35,575
	Thereafter		32,611
	Total		3,345,057
	Less interest		357,186
	Present value of minimum lease payments		2,987,871
	Less current portion of capital lease obligations		727,307
	Capital lease obligations, net of current portion	$	2,260,564

6_Stockholders_Equity_Tables

6. Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Summary of plan activity	Shares approved for issuance at plan inception			5,000,000
	Options granted in 2014			(1,435,000	)
	Options cancelled in 2014			10,000
	Restricted shares issued in 2014			(210,000	)
	Balance at December 31, 2014 and March 31, 2015			3,365,000
Options outstanding									Weighted
									average
					Options				exercise
					Outstanding				price
	Balance at March 31, 2015					24,225,000			$	5.47
Schedule of stock option activity					Options outstanding													Options vested and exercisable
									Weighted
									average				Weighted							Weighted
									remaining				average			Aggregate				average	Aggregate
	Exercise				Number				contractual				exercise			intrinsic		Number		exercise	intrinsic
	price				outstanding				life (years)				price			value		vested		price	value
	$2.50					9,475,000				3.37			$2.50			$	14,212,500		8,987,500	$2.50	$	13,481,250
	$5.00					7,750,000				2.99			$5.00				–		7,700,000	$5.00		–
	$10.00					7,000,000				8.01			$10.00				–		7,000,000	$10.00		–
						24,225,000							$5.47			$	14,212,500		23,687,500	$5.53	$	13,481,250
Option assumptions	During the three months ended March 31, 2014, the Company issued options to purchase a total of 100,000 shares of the Company’s common stock to an employee pursuant to terms of an employment agreement. These options had contractual lives of two years and were valued at an average grant date fair value of $0.25 per option, or $25,000, using the Black-Scholes Option Pricing Model with the following assumptions:
	Stock price	$2.50
	Expected term	1 year
	Expected volatility	24.43%
	Risk free interest rate	0.30%
	Dividend yield	0
	During the three months ended March 31, 2014, the Company issued options to purchase a total of 1,035,000 shares of the Company’s common stock to various employees. These options had contractual lives of ten years and were valued at an average grant date fair value of $0.70 per option, or $724,500, using the Black-Scholes Option Pricing Model with the following assumptions:
	Stock price	$2.50
	Expected term	5.375 years
	Expected volatility	27.72%
	Risk free interest rate	1.46%
	Dividend yield	0
	In May 2014, the Company issued options to purchase a total of 300,000 shares of the Company’s common stock to a director. These options had contractual lives of four years and were valued at an average grant date fair value of $0.18 per option, or $54,000, using the Black-Scholes Option Pricing Model with the following assumptions:
	Stock price	$2.50
	Expected term	2 years
	Expected volatility	24.43%
	Risk free interest rate	0.43%
	Dividend yield	0
Warrant transactions											Weighted
							Weighted				average
							average				remaining			Aggregate
			Number				exercise				contractual			intrinsic
			of warrants				price				term (years)			value
	Outstanding and Exercisable at December 31, 2014			300,000			$	3.33				–		$	–
	Outstanding and Exercisable at March 31, 2015			–			$	–				–		$	–
	Weighted Average Grant Date Fair Value						$	–
Basic and Diluted Income Per Share			Three Months Ended March 31,
			2015				2014
	Basic:
	Numerator - net income available to common stockholders		$	483,959				3,389,970
	Denominator - weighted-average shares outstanding			29,141,679				30,043,053
	Net income per share - Basic		$	0.02			$	0.11
	Diluted:
	Numerator:
	Net income available to common stockholders		$	483,959			$	3,389,970
	Interest expense on convertible debt, net of taxes			46,912				3,700
				530,871				3,393,670
	Denominator:
	Weighted-average shares outstanding			29,141,679				30,043,053
	Weighted-average equivalent shares options and warrants			866,378				–
	Weighted-average equivalent shares from convertible debt			1,000,000				222,222
	Weighted-average equivalent shares from Series C convertible preferred stock			–				–
	Weighted-average equivalent shares from Series D convertible preferred stock			179,776				72,222
	Weighted-average equivalent shares from Series E convertible preferred stock			82,079				–
				31,269,912				30,337,497
	Net income per share - Diluted		$	0.02			$	0.11
Antidilutive Securities			March 31,
			2015				2014
	Stock options outstanding			24,225,000				23,995,000
	Warrants outstanding			–				346,400
				24,225,000				24,341,400

7_Income_Taxes_Tables

7. Income Taxes (Tables)	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income tax provision		Three Months Ended March 31,
		2015			2014
	Current provision:
	Federal	$	792,900		$	3,327,000
	State		135,700			569,500
	Deferred provision:
	Federal		44,100			(1,173,200	)
	State		4,800			(125,200	)
		$	977,500		$	2,598,100
Reconciliation of the statutory federal income tax rate		Three Months Ended March 31,
		2015			2014
	Expected federal income tax at 34% statutory rate		34.00%			34.00%
	State income taxes		4.70%			4.20%
	Permanent differences		10.60%			-0.60%
			49.30%			37.60%
Deferred Tax Liability		March 31,			December 31,
		2015			2014
	Deferred income tax assets:
	Allowance for bad debts	$	28,300		$	28,300
	Stock options		444,400			423,200
	Total deferred income tax assets	$	472,700		$	451,500
	Deferred income tax liabilities:
	Property and equipment	$	(558,800	)	$	(513,600	)
	Intangible amortization		(187,400	)		(162,500	)
	Total deferred income tax liabilities	$	(746,200	)	$	(676,100	)
	Net deferred income taxes:
	Current	$	28,300		$	28,300
	Non-current		(301,800	)		(252,900	)
		$	(273,500	)	$	(224,600	)

8_Business_Combinations_Tables

8. Business Combinations (Tables)	3 Months Ended
	Mar. 31, 2015
Business Combinations [Abstract]
Schedule of goodwill		March 31,		December 31,
		2015		2014
	Medical Billing Choices, Inc.	$	1,202,112	$	1,202,112
	PB Laboratories, LLC		107,124		107,124
	Biohealth Medical Laboratory, Inc.		255,634		116,763
	Clinlab, Inc.		857,532		857,532
	Medical Mime, Inc.		274,811		274,811
	Epinex Diagnostics Laboratories, Inc.		581,600		581,600
		$	3,278,813	$	3,139,942

10_Segment_Reporting_Tables

10. Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Segment information		Three Months Ended March 31,
		2015			2014
	Net revenues - External
	Laboratory Services	$	13,499,803		$	14,788,210
	Medical Support Solutions		148,979			87,329
	Corporate & Eliminations		–			–
		$	13,648,782		$	14,875,539
	Net revenues - Inter Segment
	Laboratory Services	$	–		$	–
	Medical Support Solutions		384,108			516,744
	Corporate & Eliminations		–			–
		$	384,108		$	516,744
	Income (loss) from operations
	Laboratory Services	$	5,065,421		$	7,277,346
	Medical Support Solutions		(1,357,989	)		103,476
	Corporate & Eliminations		(1,492,870	)		(516,744	)
		$	2,214,562		$	6,864,078
	Depreciation and amortization
	Laboratory Services	$	447,325		$	156,690
	Medical Support Solutions		160,356			8,998
	Corporate & Eliminations		(26,888	)		–
		$	580,793		$	165,688
	Capital expenditures
	Laboratory Services	$	187,885		$	279,381
	Medical Support Solutions		25,257			108,026
	Corporate & Eliminations		–			–
		$	213,142		$	387,407
		March 31,			December 31,
		2015			2014
	Total assets
	Laboratory Services	$	35,191,475		$	29,362,062
	Medical Support Solutions		6,330,406			5,214,139
	Corporate & Eliminations		(1,579,705	)		1,184,553
		$	39,942,176		$	35,760,754
	Intangible assets
	Laboratory Services	$	4,087,502		$	4,088,835
	Medical Support Solutions		340,922			347,638
	Corporate & Eliminations		–			–
		$	4,428,424		$	4,436,473
	Goodwill
	Laboratory Services	$	944,358		$	805,487
	Medical Support Solutions		2,334,455			2,334,455
	Corporate & Eliminations		–			–
		$	3,278,813		$	3,139,942

2_LongLived_Assets_Details

2. Long-Lived Assets (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Property and equipment, gross	$10,146,766	$9,921,616
Accumulated depreciation	-2,828,245	-2,243,493
Property and equipment, net	7,318,521	7,678,123
Medical equipment
Property and equipment, gross	922,552	896,641
Equipment
Property and equipment, gross	504,967	396,551
Capital lease assets
Property and equipment, gross	4,024,449	4,024,449
Furniture
Property and equipment, gross	412,725	333,316
Leasehold Improvements
Property and equipment, gross	1,676,405	1,665,501
Vehicles
Property and equipment, gross	177,534	177,534
Computer Equipment
Property and equipment, gross	599,081	595,571
Software
Property and equipment, gross	$1,832,053	$1,832,053

2_LongLived_Assets_Details_Nar

2. Long-Lived Assets (Details Narrative) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Property, Plant and Equipment [Abstract]
Depreciation	$580,793	$165,688

3_Notes_Payable_DetailsNotes_P

3. Notes Payable (Details-Notes Payable) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Notes payable, total	$226,684	$536,684
Less: current portion	-226,684	-443,292
Notes payable, net of current portion	0	93,392
Acquisition note No. 1
Notes payable, total	0	250,000
Loan payable to former shareholder of Epinex
Notes payable, total	$226,684	$286,684

3_Notes_Payable_DetailsRelated

3. Notes Payable (Details-Related Party) (USD $)	Mar. 31, 2015
Notes payable - related parties [Member]
Face Value of Note	$6,030,000
Put Discount	-753,425
Put Premium	1,000,000
Debt Discount	-286,301
Net Value of Note	5,990,274
Convertible Debt [Member]
Face Value of Note	3,000,000
Put Discount	-753,425
Put Premium	1,000,000
Debt Discount	-286,301
Net Value of Note	2,690,274
Loan payable to Alcimide [Member]
Face Value of Note	3,000,000
Net Value of Note	3,000,000
Loan payable to Alcimide 2 [Member]
Face Value of Note	30,000
Net Value of Note	$30,000

3_Notes_Payable_Details_Narrat

3. Notes Payable (Details Narrative) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Debt Disclosure [Abstract]
Gain on settlement of debt	$275,028	$0

4_Related_Party_Transactions_D

4. Related Party Transactions (Details Narrative) (USD $)	3 Months Ended
	Mar. 31, 2015
Alcimede [Member]
Proceeds from related parties	$30,000
Repayments of related party debt	30,000
Alcimede
Proceeds from related parties	3,000,000
D & D Funding [Member]
Proceeds from related parties	$3,000,000

5_Capital_Lease_Obligations_De

5. Capital Lease Obligations (Details-Capital leased assets) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Capital Lease Obligations [Abstract]
Medical equipment	$4,024,449	$4,024,449
Less accumulated depreciation	-1,098,060	-883,015
Net	$2,926,389	$3,141,434

5_Capital_Lease_Obligations_De1

5. Capital Lease Obligations (Details-Future payments) (USD $)	Mar. 31, 2015	Dec. 31, 2014
December 31,
2015	$846,860
2016	1,078,010
2017	969,606
2018	382,395
2019	35,575
Thereafter	32,611
Total	3,345,057
Less interest:	357,186
Present value of minimum lease payments	2,987,871
Less current portion of capital lease obligations	727,307	962,562
Capital lease obligations, net of current portion	$2,260,564	$2,222,625

5_Capital_Lease_Obligations_De2

5. Capital Lease Obligations (Details Narrative) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Capital Lease Obligations Details Narrative
Depreciation expense on capital leases	$215,045	$54,980

6_Stockholders_Equity_Details_

6. Stockholders' Equity (Details - 2013 Plan activity) (2013 Equity Plan)	3 Months Ended
	Mar. 31, 2015
2013 Equity Plan
Options outstanding
Options outstanding, beginning balance	5,000,000
Options granted	-1,435,000
Options cancelled or expired	10,000
Restricted shares issued	-210,000
Options outstanding, ending balance	3,365,000

6_Stockholders_Equity_DetailsO

6. Stockholders Equity (Details-Option to employees and directors) (Employees and Directors, Stock Options, USD $)	3 Months Ended
	Mar. 31, 2015
Options Outstanding - Employees and Directors
Options outstanding	24,225,000
Weighted average exercise price - outstanding	$5.47
Aggregate intrinsic value - outstanding	$14,212,500
Options Vested and Exercisable - Employees and Directors
Options vested	23,687,500
Weighted average exercise price - vested and exercisable	$5.53
Aggregate intrinsic value - vested and exercisable	13,481,250
Exercise price $2.50
Options Outstanding - Employees and Directors
Options outstanding	9,475,000
Weighted average remaining contractual life	3 years 4 months 13 days
Weighted average exercise price - outstanding	$2.50
Aggregate intrinsic value - outstanding	14,212,500
Options Vested and Exercisable - Employees and Directors
Options vested	8,987,500
Weighted average exercise price - vested and exercisable	$2.50
Aggregate intrinsic value - vested and exercisable	13,481,250
Exercise price $5.00
Options Outstanding - Employees and Directors
Options outstanding	7,750,000
Weighted average remaining contractual life	2 years 11 months 26 days
Weighted average exercise price - outstanding	$5
Aggregate intrinsic value - outstanding	0
Options Vested and Exercisable - Employees and Directors
Options vested	7,700,000
Weighted average exercise price - vested and exercisable	$5
Aggregate intrinsic value - vested and exercisable	0
Exercise price $10.00
Options Outstanding - Employees and Directors
Options outstanding	7,000,000
Weighted average remaining contractual life	8 years 4 days
Weighted average exercise price - outstanding	$10
Aggregate intrinsic value - outstanding	0
Options Vested and Exercisable - Employees and Directors
Options vested	7,000,000
Weighted average exercise price - vested and exercisable	$10
Aggregate intrinsic value - vested and exercisable	$0

6_Stockholders_Equity_DetailsW

6. Stockholders Equity (Details-Warrants) (Warrant, USD $)	Mar. 31, 2015	Dec. 31, 2014
Warrant
Number of warrants
Warrants outstanding - beginning balance	0	300,000
Warrants oustanding - ending balance	0	300,000
Weighted average exercise price
Warrants outstanding - beginning balance	$0	$3.33
Warrants outstanding - ending balance	$0	$3.33

6_Stockholders_Equity_Earnings

6. Stockholders Equity Earnings (Details-EPS) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Basic:
Net income (loss) attributable to Medytox Solutions common shareholders	$483,959	$3,389,970
Weighted average number of shares outstanding during the period - Basic	29,141,679	30,043,053
Basic net loss per share attributable to common stockholders	$0.02	$0.11
Diluted:
Net income available to common stockholders	483,959	3,389,970
Interest expense on convertible debt, net of taxes	46,912	3,700
Diluted net income	$530,871	$3,393,670
Weighted-average shares outstanding	29,141,679	30,043,053
Weighted-average equivalent shares options and warrants	866,378	0
Weighted-average equivalent shares from convertible debt	1,000,000	222,222
Diluted Shares Outstanding	31,269,912	30,337,497
Net income per share - Diluted	$0.02	$0.11
Convertible Series C Preferred Stock
Diluted:
Weighted-average equivalent shares from convertible preferred stock	0	0
Series D preferred stock
Diluted:
Weighted-average equivalent shares from convertible preferred stock	179,776	72,222
Series E preferred stock
Diluted:
Weighted-average equivalent shares from convertible preferred stock	82,079	0

6_Stockholders_Equity_Details_1

6. Stockholders' Equity (Details - Antidilutive shares)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Antidilutive securities	24,225,000	23,341,400
Stock Options
Antidilutive securities	24,225,000	23,995,000
Warrant
Antidilutive securities	0	346,400

6_Stockholders_Equity_Details_2

6. Stockholders' Equity (Details Narrative) (USD $)	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Unrecognized compensation costs	$2,959
Unrecognized compensation weighted average amortization period	1 month 28 days

7_Income_Taxes_DetailsIncome_t

7. Income Taxes (Details-Income tax components) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Current provision:
Federal	$792,900	$3,327,000
State	135,700	569,500
Deferred provision:
Federal	44,100	-1,173,200
State	4,800	-125,200
Provision for income taxes	$977,500	$2,598,100

7_Income_Taxes_DetailsEffectiv

7. Income Taxes (Details-Effective income tax rate)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Income Tax Disclosure [Abstract]
Expected federal income tax at 34% statutory rate	34.00%	34.00%
State income taxes	4.70%	4.20%
Permanent differences	10.60%	-0.60%
Income tax provision (benefit)	49.30%	37.60%

7_Income_Taxes_DetailsDeferred

7. Income Taxes (Details-Deferred income taxes) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Deferred tax assets:
Allowance for bad debts	$28,300	$28,300
Stock options	444,400	423,200
Total deferred tax assets	472,700	451,500
Deferred tax liabilities:
Property and equipment	-558,800	-513,600
Intangible amortization	-187,400	-162,500
Total deferred liabilities	-746,200	-676,100
Net deferred income taxes:
Current	28,300	28,300
Non-current	-301,800	-252,900
Net deferred tax	($273,500)	($224,600)

8_Business_Combinations_Detail

8. Business Combinations (Detail-Goodwill) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Goodwill	$3,278,813	$3,139,942
Medical Billing Choices
Goodwill	1,202,112	1,202,112
PB Laboratories
Goodwill	107,124	107,124
Biohealth Medical Laboratory
Goodwill	255,634	116,763
Clinlab, Inc.
Goodwill	857,532	857,532
Medical Mime, Inc.
Goodwill	274,811	274,811
Epinex Diagnostics Laboratories, Inc.
Goodwill	$581,600	$581,600

10_Segment_Reporting_Details

10. Segment Reporting (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Net revenues - External	$13,648,782	$14,875,539
Net revenues - Inter Segment	384,108	516,744
Income (loss) from operations	2,214,561	6,864,078
Depreciation and amortization	580,793	165,688
Capital expenditures	213,142	387,407
Total assets	39,942,176		35,760,754
Intangible assets	4,428,424		4,436,473
Goodwill	3,278,813		3,139,942
Laboratory Services
Net revenues - External	13,499,803	14,788,210
Net revenues - Inter Segment	0	0
Income (loss) from operations	5,065,421	7,277,346
Depreciation and amortization	447,325	156,690
Capital expenditures	187,885	279,381
Total assets	35,191,475		29,362,062
Intangible assets	4,087,502		4,088,835
Goodwill	944,358		805,487
Medical Support Solutions
Net revenues - External	148,979	87,329
Net revenues - Inter Segment	384,108	516,744
Income (loss) from operations	-1,357,989	103,476
Depreciation and amortization	160,356	8,998
Capital expenditures	25,257	108,026
Total assets	6,330,406		5,214,139
Intangible assets	340,922		347,638
Goodwill	2,334,455		2,334,455
Corporate & Eliminations
Net revenues - External	0	0
Net revenues - Inter Segment	0	0
Income (loss) from operations	-1,492,870	-516,744
Depreciation and amortization	-26,888	0
Capital expenditures	0	0
Total assets	-1,579,705		1,184,553
Intangible assets	0		0
Goodwill	$0		$0